Asthma is the chronic respiratory disease which mainly affects the airways of the lung, characterized by wheezing, coughing, breathlessness, and chest tightness. Asthma can be caused by genetic or environmental factors. There is no cure for asthma but it can be controlled by using different medications. Unknown etiology of the disease is a major challenge to the asthma therapeutic market.

The report titled “Global Asthma Therapeutics Market- Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the overall asthma therapeutics market along with the market size and estimates for the duration 2023 to 2030. The research study covers in-depth analysis of market segments based on drug class, product type, route of administration and different geographical region.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global asthma therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global asthma therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global asthma therapeutics market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report. 

Asthma is a chronic lung disease currently no cure, but symptoms can be controlled by using medications. Anti-inflammatory drugs such as inhaled corticosteroids, leukotriene modifiers, mediator release inhibitors and theophylline are long term asthma control medications used to keep asthma under control. Bronchodilators are quick acting, short term symptoms relief medication including drugs such as beta agonists, methylxanthines and intravenous corticosteroids.  

In base year 2021, combination therapy held the largest market in the global asthma therapeutics market. In combination therapy, patients are treated with inhaled corticosteroids (ICS) with long-acting beta agonists (LABA), example of this class is advair by GlaxoSmithKline. Global market of combination therapy will experience a moderate growth during forecast period because of the rise in patient compliance for combination therapy, as it is administered as a once daily dose. In addition to this presence of late stage pipeline molecule in combination therapy would further drive the market growth. Global bronchodilator market will experience a sluggish growth during the forecast period because of the patent expiries of major brands which leads to the entry of generic drugs and erosion of sales of branded drugs. Due to emerging trends such as the use of biologics and the increasing use of bronchodilators in combination with corticosteroid would further drive the global bronchodilators market. Currently, only one biologic Xolair (omalizumab) is approved as add on therapy for the treatment of asthma. The market will be hit by further patent expirations as Xolair and Spiriva in 2017 and 2018 respectively. Anti-inflammatory drugs such as leukotriene antagonists, mast cell stabilizers will steadily grow during forecast period, as limited use of these drugs in the market because of the increasing popularity of the of daily combination therapeutics.

In the base year 2021, metered dose inhalers (MDIs) was observed as the largest revenue generating segment and is anticipated to grow further during the forecast period 2021 to 2029. MDI used as asthma rescue inhalers or reliever medicines generally contain bronchodilator, corticosteroid or a combination of both drugs. Major advantages of MDI is they deliver a consistent dose of medication directly to the lungs. However MDIs are not very efficient to use as they release environmentally hazardous gases, which is negatively impacting the market growth of the MDIs segment. Dry Powder Inhalers (DPIs) will be the most lucrative market segment during the forecast period because consumption pattern is shifting to the DPIs, as these are easier to use than MDIs also have some sort of in built dose counter. However DPIs have some disadvantages such as DPIs are more susceptible to contamination and more expensive, which hinder the market growth during forecast period. Mist inhaler is the novel drug delivery system developed in past decades, deliver metered dosage of medication. Currently only one mist inhaler, Respimat by Boehringer Ingelheim is available in European countries. Nebulizer convert liquid medicine into vapor or mist so that it can be inhaled directly. Certain advantage associated with nebulizer includes immediate application of medicine, easy to use, ideal option for home healthcare use for debilitated patients and geriatrics contributing the market growth of global asthma market. However major disadvantage with use of nebulizer includes it requires a power source, expensive and bulkier to use, which negatively impacting market growth of nebulizer. Increased prevalence of asthma, rise in health awareness and increased demand for respiratory inhaler devices play a major role in the growing global asthma device market.

In the base year 2021, inhaled drugs segment was the largest revenue generating segment in global asthma therapeutic market, due to advantages associated with use of inhalation drug therapy such as rapid onset of action, less systemic toxicity and higher concentration availability at the site of action. Bronchodilators, corticosteroids are usually given by inhalation route. Matered dose inhaler, dry powder inhaler and nebulizer are generally used to deliver inhalation drug in asthma. Use of inhaled corticosteroids in combination therapy is a therapeutic trend observed in the market. The rise in the incidence of asthma, increasing compliance for the inhalation asthma therapeutics provide opportunities for manufacturers to invest in the inhaler device market. GlaxoSmithKline's Advair, Boehringer Ingelheim's Spiriva, AstraZeneca’s Symbicort are the major contributors in inhaled asthma drug market. However patent expiry of some blockbusters drugs such as Symbicort and Flovent leads to reduce the overall revenue in global inhalation drug market. Theophylline, corticosteroids in combination with short-acting beta agonists and Leukotriene modifiers are generally given by oral route to treat asthma. Oral blockbuster drug Singulair manufactured by Merck is currently suffering sales losses due to generic counterparts available in the market. Corticosteroids, aminophyllines, β2-agonist are generally given by parenteral route. Intravenous drug therapy is recommended when inhaled therapy cannot be used, such as in emergency conditions. Novartis’s blockbuster drug Xolair is given by subcutaneous route and it is the only biologic therapy licensed in many countries for the treatment of asthma.

Asthma is a chronic lung disease of the airways that causes recurring episodes of wheezing, breathlessness, chest tightness and coughing. For the treatment of asthma bronchodilators and anti-inflammatory drugs are generally prescribe depending on the disease condition.

In base year 2021, North America was largest contributor in global asthma therapeutics market and occupied a significant portion of the global market. Higher prices of asthma medications and the lack of generic asthma inhalers drives the US asthma market. North America market will grow faster during forecast period due to increasing pollution coupled with a rise prevalence of asthma, expected launch of pipeline molecules and a delay in the surge of generic competition in this market. Also high cost of treatment and increasing demand of asthma therapeutics contribute the market growth in this region. Europe is the second largest market in terms of revenue for asthma therapeutics and it is anticipated to grow steady rate during forecast period. The prevalence of asthma increased in the latter part of the 20th century, but now prevalence is stable in many European countries. The market in the Europe is dominated by the UK, Germany, France, Italy, and Spain. In some countries such as Finland and France, the active participation of government health departments for asthma control would further drive the market in this regions. Key factor such as economic development, increasing healthcare awareness, high growth rate, rising funding by government agencies and private organizations in Asia Pacific region expected to drive the market growth throughout the forecast period 2023-2030. China, Japan, South Korea, India, and Australia dominate the global asthma market in the Asia Pacific region.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Asthma Therapeutics market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Asthma Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Asthma Therapeutics market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Asthma Therapeutics market?
• Which is the largest regional market for Asthma Therapeutics market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Asthma Therapeutics market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Asthma Therapeutics market worldwide?